{
    "clinical_study": {
        "@rank": "134668", 
        "arm_group": [
            {
                "arm_group_label": "Semaglutide 0.5 mg", 
                "arm_group_type": "Experimental", 
                "description": "Dose-escalation trial"
            }, 
            {
                "arm_group_label": "Semaglutide placebo 0.5 mg", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Semaglutide 1.0 mg", 
                "arm_group_type": "Experimental", 
                "description": "Dose-escalation trial"
            }, 
            {
                "arm_group_label": "Semaglutide placebo 1.0 mg", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Asia. The aim of the trial is to investigate the pharmacokinetics\n      (the exposure of the trial drug in the body), pharmacodynamics (the effect of the\n      investigated drug on the body), and the safety and tolerability of semaglutide in healthy\n      male Japanese and Caucasian subjects."
        }, 
        "brief_title": "A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 2", 
            "Healthy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male Japanese and Caucasian subjects\n\n          -  Age between 20 and 55 years (both inclusive) at the time of signing informed consent\n\n          -  Body weight of equal to or above 54.0 kg\n\n          -  Body mass index (BMI) between 20.0 and 25.0 kg/m^2 (both inclusive)\n\n          -  Glycosylated haemoglobin A1c (HbA1c) below or equal to 6.0%\n\n          -  For Japanese subjects only: both parents Japanese\n\n          -  For Caucasian subjects only: both parents Caucasian\n\n        Exclusion Criteria:\n\n          -  Any clinically significant disease history, in the opinion of the investigator, or\n             systemic or organ disease including: cardiological, pulmonary, gastrointestinal,\n             hepatic, neurologic, renal, genitourinary and endocrine, dermatologic or hematologic\n             diseases\n\n          -  Personal or family history of medullary thyroid carcinoma or multiple endocrine\n             neoplasia syndrome type 2 (MEN2)\n\n          -  History of chronic pancreatitis or idiopathic acute pancreatitis\n\n          -  Calcitonin above or equal to 50 ng/L\n\n          -  History of alcohol abuse within 1 year from screening, or a positive result in the\n             alcohol breath test, or consumption of more than 21 units of alcohol weekly: 1 unit\n             of alcohol equals approximately 250 mL of beer or lager, or approximately120 mL (one\n             glass) of wine or Japanese sake, or approximately 20 mL of spirits\n\n          -  Smoking of more than 5 cigarettes (including nicotine substitute products) or the\n             equivalent, per day or unwilling to refrain from smoking whenever required for the\n             trial procedure\n\n          -  Use of prescription drugs within 3 weeks or 5 times the half-life, whichever is\n             longer, prior to Visit 2 (randomisation), non-prescription drugs within 1 week prior\n             to Visit 2 (randomisation). The use of vitamins, minerals and nutritional\n             supplements, and the occasional use of paracetamol (acetaminophen) or acetylsalicylic\n             acid are permitted"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "44", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02146079", 
            "org_study_id": "NN9535-3634", 
            "secondary_id": [
                "U1111-1147-6660", 
                "JapicCTI-142550"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Semaglutide 0.5 mg", 
                    "Semaglutide 1.0 mg"
                ], 
                "description": "Subjects will be randomised to receive either semaglutide 0.5 mg, semaglutide 0.5 mg placebo, semaglutide 1.0 mg or semaglutide 1.0 mg placebo within each group. Treatment with active drug or placebo blinded within each dose level. After randomisation, the subjects will follow a fixed dose escalation. The maintenance dose of 0.5 mg will be reached after 4 weeks of 0.25 mg. The maintenance dose of 1.0 mg will be reached after 8 weeks (4 weeks) of 0.25 mg and 4 weeks of 0.5 mg). Once-weekly subcutaneous (s.c., under the skin) administration. Trial duration per subject is 18 to 21 weeks depending on the individual subject's schedule", 
                "intervention_name": "semaglutide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Semaglutide placebo 0.5 mg", 
                    "Semaglutide placebo 1.0 mg"
                ], 
                "description": "Subjects will be randomised to receive either semaglutide 0.5 mg, semaglutide 0.5 mg placebo, semaglutide 1.0 mg or semaglutide 1.0 mg placebo within each group. Treatment with active drug or placebo blinded within each dose level. After randomisation, the subjects will follow a fixed dose escalation. The maintenance dose of 0.5 mg will be reached after 4 weeks of 0.25 mg. The maintenance dose of 1.0 mg will be reached after 8 weeks (4 weeks) of 0.25 mg and 4 weeks of 0.5 mg). Once-weekly subcutaneous (s.c., under the skin) administration. Trial duration per subject is 18 to 21 weeks depending on the individual subject's schedule.", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 28, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Tokyo", 
                    "country": "Japan", 
                    "zip": "130-0004"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Single-centre, Parallel-group, Randomised, Double-blind, Placebocontrolled, Multiple-dose Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects", 
        "overall_contact": {
            "email": "clinicaltrials@novonordisk.com", 
            "last_name": "Novo Nordisk"
        }, 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Area under the plasma semaglutide concentration\u2212time curve", 
            "safety_issue": "No", 
            "time_frame": "During a dosing interval (0\u2212168 hours) at steady state"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02146079"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Maximum observed plasma semaglutide concentration at steady state", 
                "safety_issue": "No", 
                "time_frame": "0\u2212168 hours after the last dose of semaglutide (0.5 and 1.0 mg)"
            }, 
            {
                "measure": "Change in body weight from baseline to the end of treatment", 
                "safety_issue": "No", 
                "time_frame": "Day 1 of Visit 2 (2-21 days after Visit 1), Day 92"
            }, 
            {
                "measure": "Number of treatment emergent adverse events (TEAEs) from baseline to follow-up", 
                "safety_issue": "No", 
                "time_frame": "From Day 1 of Visit 2 (2-21 days after Visit 1) to Day 120\u2212127 (Visit 23)"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}